BioXell S.p.A. Shareholders unanimously approve all Board of Directors' proposals at Annual General Meeting

BioXell S.p.A. Shareholders unanimously approve all Board of Directors' proposals at Annual General Meeting
Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement.
Milan, Italy, April 24, 2007 - Shareholders of BioXell S.p.A. (SWX:BXLN) unanimously approved all items proposed by the Board ofDirectors at today's Annual General Meeting in Zurich.
These included: * the approval of the 2006 statutory financial statements of BioXell S.p.A. * the appointment of Dr. Werner Lanthaler as member of the Board of Directors * the re-election of KPMG S.p.A. as External Auditors of the company * the increase of the authorized capital reserved to the beneficiaries of the company's stock Option plan * the increase of the authorized capital reserved for strategic investments up to a maximum of 50% of the existing share capital, thus granting the company the flexibility to actively pursue strategic investments and in-licensing of complementary therapeutics within its areas of focus.The Annual General Meeting was attended by Shareholders whorepresented 54.87% of the total share capital of the Company.Dr. Thomas Szucs, Chairman of BioXell, commented, "It's an excitingtime to be a Shareholder and participate in the BioXell story, as theCompany enters a new phase in its maturation, with the goal ofbecoming a fully integrated biopharmaceutical company and a keyplayer in the management of urological disorders. BioXell reached keymilestones in 2006 in the development of Elocalcitol for two majorurological disorders, Benign Prostatic Hyperplasia and OveractiveBladder, either of which represents a potential blockbuster marketfor the Company's lead compound. Furthermore, Elocalcitol will beentering clinical trials for a third indication, Male Infertility,later this year, while a new compound acquired from Roche will beadvanced into Phase II trials for Post-Surgical Adhesions in 2008."About BioXellBioXell (SWX: BXLN) is a biopharmaceutical company focused on thediscovery and development of drugs that exploit novel mechanisms ofaction to treat important urological, inflammatory, and related disorders with significant unmet medical needs. The Company wasfounded in 2002 as a spin-out from Roche. BioXell's strategic goal isto become a fully integrated pharmaceutical company by maximizing thecommercial potential of its product Portfolio and leveraging existingplatforms into profitable partnerships.BioXell's lead compound, Elocalcitol, derived from its proprietaryVD3 (Vitamin D3) technology platform, is in Phase II clinical trialsfor Benign Prostatic Hyperplasia (BPH) and Overactive Bladder (OAB),with a third Phase II trial for Male Infertility scheduled for 2007.In addition, the Company has several follow-on programs based on bothVD3 and other technological platforms. BXL746 is to enter Phase IItrials for Post-Surgical Adhesions in 2008. In 2006, BioXellin-licensed from Lay Line Genomics S.p.A. a novel anti-TrkAmonoclonal antibody, MNAC13, which represents an innovative newapproach to the treatment of pain. BioXell also has an exclusivepartnership with Merck & Co., Inc. since 2005 for the development ofits TREM platform, with TREM-1 in development for the treatment ofseptic shock.In June 2006, BioXell listed its shares on the main segment of theSWX Swiss Exchange. BioXell currently employs 60 people and has sitesin Milan, Italy and Nutley, NJ, USA. More information on BioXell can be found at: http://www.bioxell.com